Compared with chemotherapy, although EGFR-TKIs were reported to pass through BBB and reduce BM among EGFR-mutated NSCLC patients [25, 26], there remain some patients developing metachronous BM during the course of EGFR-TKIs therapy. Here, EGFR is linked to non-small cell lung carcinoma.